trending Market Intelligence /marketintelligence/en/news-insights/trending/ufexxfz2vcubdusb9zmqwa2 content esgSubNav
In This List

Theravance secures J&J backing for inflammatory bowel disease drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Theravance secures J&J backing for inflammatory bowel disease drug

Theravance Biopharma Inc. has secured Johnson & Johnson's backing to develop its drug candidate TD-1473 for the treatment of inflammatory bowel diseases, including ulcerative colitis and Crohn's disease.

The U.S. pharma giant will pay Theravance $100 million as part of a global co-development and commercialization agreement, which allows Johnson & Johnson to receive an exclusive license for the drug candidate once it completes certain phase 2 clinical trials.

If Johnson & Johnson exercises the option, it will pay an additional $200 million and will be responsible for the development of the drug as a treatment for Crohn's disease while Theravance Biopharma will lead development in ulcerative colitis.

Theravance will be eligible to receive milestone payments of $700 million and will have the option to co-commercialize the drug in the U.S., while Johnson & Johnson will commercialize the product outside the U.S.

The company will also receive royalties on sales of the product outside the U.S.

TD-1473 is a treatment that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes. In contrast to other oral JAK inhibitors under development for inflammatory bowel disease, TD-1473 is specifically designed to act directly at the site of inflammation, thereby limiting systemic exposure.